First Barth syndrome treatment
Forzinity received accelerated FDA approval in 2025 for a defined population, establishing a real—but tightly bounded—clinical application for elamipretide.
P—24 • Approved rare-disease and mitochondrial research profile
Elamipretide(Also known as SS-31, Bendavia, MTP-131)
A cardiolipin-binding mitochondrial tetrapeptide with an FDA-approved rare-disease application and continuing research across cellular-energy models.
Name
Elamipretide
Also known as SS-31, Bendavia, or MTP-131; FDA-approved product: Forzinity
- Scientific classification
- Synthetic aromatic-cationic tetrapeptide and mitochondrial cardiolipin binder
- Library family
- Metabolic
- Regulatory status
- FDA granted accelerated approval to Forzinity in September 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg
Compound overview
A mitochondrial research peptide that became the first FDA-approved treatment specifically for Barth syndrome.
Elamipretide is a four-amino-acid peptide designed to concentrate at the inner mitochondrial membrane and associate with cardiolipin, a specialized phospholipid that helps organize membrane curvature and energy-producing protein complexes. Researchers have studied whether that interaction can support mitochondrial structure, electron flow, and cellular energy production under stress.
Barth syndrome is an ultra-rare inherited disorder involving tafazzin and abnormal cardiolipin remodeling. The elamipretide development program included a small randomized crossover study and a long open-label extension. The crossover study did not meet its original primary endpoints, but longer-term evidence and analyses of knee-extensor muscle strength contributed to FDA's accelerated-approval decision.
On September 19, 2025, FDA approved Forzinity as the first treatment specifically for Barth syndrome in adults and children weighing at least 30 kilograms. The approval is based on improved knee-extensor muscle strength, an intermediate endpoint considered reasonably likely to predict patient benefit. A randomized, double-blind, placebo-controlled post-approval trial is required to confirm that the strength measurement translates into meaningful benefit.
The approval is both important and narrow. FDA's trial snapshot describes 12 participants at one U.S. site, and the approved prescribing information reports injection-site reactions as the most common adverse effects while also noting serious reactions. Findings for the regulated Forzinity product cannot establish the identity, purity, safety, or performance of materials marketed under research names such as SS-31.
Research is continuing beyond Barth syndrome. A 2026 study in mitochondrial trifunctional-protein-deficient mice and patient-derived cells reported improved exercise endurance and selected mitochondrial measurements, with possible genotype-dependent cell responses but no change in cardiolipin content. Another 2026 heart-failure model found modest improvements in mitochondrial respiration without corresponding improvements in cardiac function or mitochondrial structure. Together, these studies show that mitochondrial effects can be measurable yet highly dependent on the disease model and outcome being tested.
Research beyond Barth syndrome
New preclinical work is exploring fatty-acid oxidation disorders and heart-failure models, with results that vary by tissue, genotype, and endpoint.
Confirming patient benefit
The required post-approval trial must determine whether the muscle-strength endpoint translates into meaningful everyday benefit.
Mechanism under study
Cardiolipin-associated organization of mitochondrial energy systems
Elamipretide is studied at the inner mitochondrial membrane, where cardiolipin helps organize the structures and protein complexes responsible for cellular energy production.
Cardiolipin binding
The peptide associates with cardiolipin-rich membranes and is studied for effects on membrane organization, curvature, and the positioning of respiratory proteins.
Electron transport
Laboratory models examine whether elamipretide can stabilize energy-producing protein assemblies, influence electron flow, and reduce damaging redox imbalance.
Cellular energetics
Clinical and preclinical studies measure ATP-producing capacity, muscle performance, exercise response, and tissue-specific mitochondrial function.
A measurable change in mitochondrial respiration, ATP capacity, or muscle strength does not automatically translate into broader function, disease modification, anti-aging effects, or benefits outside the exact population studied.
Current research areas
Questions under investigation
- How mitochondrial membranes organize the systems that produce cellular energy
- How abnormal cardiolipin affects muscle and heart function in Barth syndrome
- Whether changes in muscle strength improve daily activity and quality of life
- Why different genetic and disease models respond differently
- Long-term safety and results from the required confirmatory trial
Evidence summary
A genuine rare-disease breakthrough with carefully defined boundaries
- Defined clinical milestone: Forzinity is the first FDA-approved treatment specifically for Barth syndrome and targets a central feature of the disease's mitochondrial biology.
- Muscle-strength endpoint: Accelerated approval was based on improvement in knee-extensor muscle strength in the approved population.
- Mitochondrial research platform: Elamipretide gives researchers a direct way to study cardiolipin-associated membrane organization and cellular energetics.
- Rare-disease expansion: New laboratory work is testing whether related mitochondrial defects respond in models of fatty-acid oxidation disorders.
- Context-specific insight: Mixed findings across heart, skeletal muscle, cells, and animal models help identify which mitochondrial measurements may—or may not—predict meaningful function.
Accelerated approval applies only to the regulated Forzinity product and labeled Barth syndrome population. Continued approval may depend on confirmation of patient benefit, and current evidence does not establish general mitochondrial, athletic, wellness, or anti-aging benefits.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, prescribing guidance, dosing information, or instructions for elamipretide, SS-31, or Forzinity use. FDA approval applies only to the approved Forzinity product for adults and children with Barth syndrome weighing at least 30 kg. It does not apply to research-market SS-31 materials, other formulations, other conditions, or general wellness claims. Research products should not be assumed to match the approved drug in identity, purity, manufacturing, safety, or performance.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.